Cyclo Therapeutics Inc
NASDAQ:CYTH
Cyclo Therapeutics Inc
Interest Income Expense
Cyclo Therapeutics Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
Interest Income Expense
$233.8k
|
CAGR 3-Years
186%
|
CAGR 5-Years
88%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$663m
|
CAGR 3-Years
38%
|
CAGR 5-Years
3%
|
CAGR 10-Years
-8%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$630.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Cyclo Therapeutics Inc's Interest Income Expense?
Interest Income Expense
233.8k
USD
Based on the financial report for Mar 31, 2024, Cyclo Therapeutics Inc's Interest Income Expense amounts to 233.8k USD.
What is Cyclo Therapeutics Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
88%
The average annual Interest Income Expense growth rates for Cyclo Therapeutics Inc have been 186% over the past three years , 88% over the past five years .